2. Academic Validation
  3. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy

Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy

  • Biomed Pharmacother. 2020 Sep;129:110397. doi: 10.1016/j.biopha.2020.110397.
Xiaoqing Hu 1,  Meihui Xia 2,  Jiabin Wang 3,  Huimei Yu 3,  Jiannan Chai 2,  Zejun Zhang 3,  Yupei Sun 3,  Jing Su 4,  Liankun Sun 5
Affiliations

Affiliations

  • 1 Key Laboratory of Pathobiology, Ministry of Education, Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun 130021, Jilin, China; The First Hospital of Jilin University, Changchun 130021, Jilin, China.
  • 2 The First Hospital of Jilin University, Changchun 130021, Jilin, China.
  • 3 Key Laboratory of Pathobiology, Ministry of Education, Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun 130021, Jilin, China.
  • 4 Key Laboratory of Pathobiology, Ministry of Education, Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun 130021, Jilin, China. Electronic address: sujing@jlu.edu.cn.
  • 5 Key Laboratory of Pathobiology, Ministry of Education, Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun 130021, Jilin, China. Electronic address: sunlk@jlu.edu.cn.
PMID: 32585451 DOI: 10.1016/j.biopha.2020.110397
Abstract

The phosphoinositide 3-kinase (PI3K) /Akt/mammalian target of rapamycin (mTOR) signaling pathway is frequently mutated in cancers, leading to increased cell proliferation, migration, and chemoresistance. Currently, a number of small molecule inhibitors of the PI3K/Akt/mTOR signaling pathway have been assessed in preclinical and clinical studies. It has been found that dual PI3K/mTOR inhibitors may inhibit cell proliferation and induce Apoptosis in cancers, but the mechanism is still being explored. Therefore, determining the role of dual PI3K/mTOR inhibitors PKI-402 in Cancer cells may facilitate overcoming chemoresistance. By referring to a gene database and screening gene sequences, we found that human ovarian Cancer epithelial cell lines SKOV3 and A2780 had mutations of the PIK3CA gene, which might be relatively sensitive to dual-targeted PI3K/mTOR inhibitors. In this study, our data indicated that dual PI3K/mTOR Inhibitor PKI-402 disrupted the balance of Bcl-2 Family proteins by degrading the Mcl-1 protein through Autophagy. Moreover, the Autophagy receptor protein p62 bound to Mcl-1 through its ubiquitin-associated domain (UBA domain) to participate in the degradation of Mcl-1 through Autophagy. This offers hope for the treatment of ovarian Cancer patients with mutations of the PI3K/Akt/mTOR pathway.

Keywords

Apoptosis; Autophagy; Cell growth; Mcl-1; PI3K/AKT/mTOR; p62.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15244
    99.95%, PI3Kα抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z